Monitor actual ATM sales volume and pace; the company has broad discretion over timing and amount. No immediate catalyst, watch for subsequent prospectus supplements or 10-Q disclosures revealing utilization. The ATM provides financial flexibility but will dilute existing holders over time.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 22 $85.17entry
- T+1 · 5mo ago −0.20%α +1.25% · $85.00
- T+5 · 5mo ago +17.22%α +19.29% · $99.84
- T+20 · 4mo ago +10.19%α +10.34% · $93.85
- T+60 · 2mo ago +62.15%α +60.40% · $138.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Twist Bioscience filed an automatic shelf registration (S-3ASR) including a base prospectus for various securities and a specific at-the-market (ATM) offering of up to $200M of common stock through TD Cowen. The ATM provides flexible capital-raising capacity for general corporate purposes, representing ~3.8% of the current $5.2B market cap. The filing is routine for a well-known seasoned issuer and does not indicate financial distress.
Key Facts
- S-3ASR filed June 18, 2026, as a well-known seasoned issuer
- Includes ATM sales agreement for up to $200M of common stock through TD Cowen
- TD Cowen commission capped at 3% of gross proceeds
- Net proceeds to be used for working capital and general corporate purposes
- As of March 31, 2026: 62,154,412 shares outstanding; net tangible book value $359.9M ($5.79/share)
- Pro forma dilution of $76.37/share at assumed $84.95 offering price
- Company has no current commitments for acquisitions or specific use of proceeds
Financial Impact
Up to $200M gross proceeds; ~3.8% dilution relative to $5.2B market cap; pro forma net tangible book value increases to ~$553.3M ($8.58/share)
Risk Factors
- Potential dilution from future ATM sales at uncertain prices
- Stock price pressure from continuous offering overhang
- Management discretion over proceeds may lead to value-destructive uses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3ASR Filing (Primary) | 0001104659-26-075726 |
| Document: tm2617605-1_s3asr.htm | 0001104659-26-075726 |
| Document: tm2617605d2_ex1-2.htm | 0001104659-26-075726 |
Track record
46 reports on TWST
8 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +55.24% at T+60 after the Aug 3, 2026 report. 10 of 12 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $105.16 Now $104.86 −0.29% settles Dec 15
- Nov 16, 2026today 144 Neutral 2/10 Entry $104.98 Now $104.86 −0.11% settles Dec 15
- Nov 16, 2026today 144 Neutral 2/10 Entry $105.61 Now $104.86 −0.71% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $104.03 Now $104.86 +0.80% settles Dec 15
- Nov 12, 20264d ago 8-K Bullish 6/10 Entry $114.22 Now $104.86 −8.19% settles Dec 11
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $114.22 Now $104.86 −8.19% settles Dec 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $132.13 Now $104.86 −20.64% settles Dec 9
- Nov 5, 202610d ago Insider Cluster Neutral 2/10 Entry $120.79 Now $104.86 −13.19% settles Dec 7
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $120.61 Now $104.86 −13.06% settles Dec 4
- Nov 4, 202611d ago Institutional Cluster Neutral 3/10 Entry $120.61 Now $104.86 −13.06% settles Dec 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers